BIIB Stocktwits, News and Mentions. Forecasting Biogen Inc. Sentiments







6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…

BIIB Stock News and Mentions of Biogen Inc. Stocktwits

Updated: March 29, 2024 (09:56)

Sector: Healthcare

Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.

We meticulously analyze the sentiment trend in each article for the last 60 days where Biogen Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Biogen Inc. (BIIB).

You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Biogen stocks.


Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles

News and Mentions of Biogen Inc. (BIIB)

March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)

Why Is Denali Therapeutics ( DNLI ) Up 2.8% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 28, 2024 (14:25) / "Zacks Commentary" (by Zacks Equity Research)

Omega Therapeutics, Inc. ( OMGA ) Reports Q4 Loss, Tops Revenue Estimates

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)

Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?

Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
In Article Trend: Neutral
March 26, 2024 (15:21) / "Zacks Commentary" (by Zacks Equity Research)

CHMP to Delay Nod on Biogen ( BIIB ) , Eisai's Alzheimer's Drug

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
In Article Trend: Neutral
March 25, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Dips More Than Broader Market: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session.
In Article Trend: Neutral
March 25, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)

Can Ionis' ( IONS ) Wholly-Owned Drugs Cut Dependency on Collabs?

Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:30) / "Benzinga" (by Globe Newswire)

Dyne Therapeutics Announces CEO Transition - Dyne Therapeutics ( NASDAQ:DYN )

- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:18) / "PR Newswire" (by Bio-Thera Solutions)

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor α

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006, an Innovative ... PR ...
In Article Trend: Neutral
March 25, 2024 (11:03) / "Zacks Commentary" (by Zacks Equity Research)

Labcorp ( LH ) Boost Diagnostics Suite With New Biomarker Test

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
In Article Trend: Somewhat-Bullish
March 22, 2024 (17:44) / "Benzinga" (by Vandana Singh)

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab Why Is Biogen Stock Falling Friday? - Biogen ( NASDAQ:BIIB )

Biogen Inc BIIB and Eisai Co Ltd ESALF ESALY faced a setback as the much-anticipated Oral Explanation slated for March 19 at the Committee for Medicinal Products for Human Use ( CHMP ) was postponed.
In Article Trend: Neutral
March 19, 2024 (11:01) / "Canada Newswire" (by Biogen Canada)

Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS

• SOD1- ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS that represents approximately two percent of all ALS cases1 • Health regulatory decision on tofersen New Drug Submission expected in early 2025
In Article Trend: Neutral
March 18, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)

Here's Why Biogen Inc. ( BIIB ) Gained But Lagged the Market Today

Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.
In Article Trend: Somewhat-Bullish
March 18, 2024 (19:45) / "Benzinga" (by Benzinga Insights)

Spotlight on Biogen: Analyzing the Surge in Options Activity - Biogen ( NASDAQ:BIIB )

Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 18, 2024 (12:00) / "PR Newswire" (by Ltd)

Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM

GUANGZHOU, China and SAN JOSÉ, Costa Rica, March 18, 2024 /PRNewswire/ -- Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, and SteinCares, one of Latin America's leading specialty healthcare companies, announced today a new ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:36) / "PR Newswire"

Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire

Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...
In Article Trend: Somewhat-Bullish
March 16, 2024 (13:15) / "Motley Fool" (by Alex Carchidi)

Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?

The drugmaker is caught up in an unexpected situation with regulators.
In Article Trend: Neutral
March 15, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)

Why Is Sage Therapeutics, Inc. ( SAGE ) Down 22% Since Last Earnings Report?

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 15, 2024 (13:15) / "Motley Fool" (by David Jagielski)

Can Eli Lilly Stock Double in 5 Years? Here's What It Would Take.

The company's valuation may be high but that doesn't mean Eli Lilly is anywhere near its peak.
In Article Trend: Somewhat-Bullish
March 14, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)

Why Is Biogen Inc. ( BIIB ) Up 2.6% Since Last Earnings Report?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 13, 2024 (11:00) / "Benzinga" (by Globe Newswire)

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer - Voyager Therapeutics ( NASDAQ:VYGR )

LEXINGTON, Mass., March 13, 2024 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer ( CMO ) , effective March 25, 2024.
In Article Trend: Neutral
March 13, 2024 (11:00) / "GlobeNewswire" (by Voyager Therapeutics)

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

LEXINGTON, Mass., March 13, 2024 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer ( CMO ) , effective March 25, 2024.
In Article Trend: Somewhat-Bullish
March 12, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Stock Falls Amid Market Uptick: What Investors Need to Know

Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 12, 2024 (15:30) / "Benzinga" (by Globe Newswire)

Proliferative Diabetic Retinopathy ( PDR ) Market Shows Rapid Growth: Market Size To Grow At A CAGR Of More Than 10% Through 2024-2028 As Per The Business Research Company's Proliferative Diabetic Retinopathy ( PDR ) Global Market Report 2024

LONDON, March 12, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Proliferative Diabetic Retinopathy ( PDR ) Global Market Report 2024, the proliferative diabetic retinopathy ( PDR ) market has experienced significant growth in recent years, with the proliferative diabetic ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:32) / "Zacks Commentary" (by Aparajita Dutta)

5 Low Leverage Stocks to Buy With CPI Data Expected to Show Hike

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy FRPT, ATR, MFC, HWKN and COLD.
In Article Trend: Somewhat-Bullish
March 11, 2024 (10:34) / "Zacks Commentary" (by Zacks Equity Research)

Lilly ( LLY ) Stock Down as FDA Delays Decision on Donanemab

The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
In Article Trend: Neutral
March 8, 2024 (16:27) / "Forbes" (by James Farrell)

What Is Donanemab? Eli Lilly's Alzheimer's Drug Gets Delayed Decision From FDA

The FDA has delayed a decision on whether it will approve donanemab, Eli Lilly's closely watched new Alzheimer's drug, despite promising study results that showed it could significantly slow cognitive and functional decline in early-symptomatic Alzheimer's patients, the pharmaceutical company ...
In Article Trend: Neutral
March 8, 2024 (15:08) / "Investors Business Daily" (by ALLISON GATLIN)

Biogen Surges On A Setback For Lilly's Rival Alzheimer's Drug

Biogen Stock Surges After FDA Delays Its Decision On Eli Lilly's Alzheimer's Treatment Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:15) / "CNBC" (by Annika Kim Constantino)

Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move

The FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's safety and efficacy.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:08) / "Investors Business Daily" (by Investor's Business Daily)

FDA Delays Decision On Eli Lilly's Alzheimer Drug

The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:45) / "CNN" (by Meg Tirrell)

Eli Lilly says Alzheimer's drug approval delayed as FDA seeks input from advisers

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last-minute meeting of its outside advisers to review the drug's safety and efficacy.
In Article Trend: Neutral
March 7, 2024 (20:19) / "Benzinga" (by Globe Newswire)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB - Biogen ( NASDAQ:BIIB )

NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ( "Biogen" or the "Company" ) BIIB. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 7, 2024 (05:46) / "Benzinga" (by PRNewswire)

BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's ( publ ) BIOA ( Stockholm: BIOA B ) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease.
In Article Trend: Neutral
March 6, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed at $217.56 in the latest trading session, marking a +0.15% move from the prior day.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:21) / "Benzinga" (by Vandana Singh)

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers - Biogen ( NASDAQ:BIIB )

Biogen Inc BIIB released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.
In Article Trend: Neutral
March 6, 2024 (12:30) / "Benzinga" (by Globe Newswire)

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® ( nusinersen ) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most ...
In Article Trend: Neutral
March 6, 2024 (12:30) / "GlobeNewswire" (by Biogen Inc.)

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® ( nusinersen ) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

CAMBRIDGE, Mass., March 06, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year ...
In Article Trend: Neutral
March 5, 2024 (22:50) / "Zacks Commentary" (by Zacks Equity Research)

Here's Why Biogen Inc. ( BIIB ) Fell More Than Broader Market

Biogen Inc. (BIIB) closed at $217.23 in the latest trading session, marking a -1.71% move from the prior day.
In Article Trend: Neutral
March 5, 2024 (17:12) / "MarketWatch" (by Jessica Hall)

'Patients got better faster': Music therapy provides new hope after strokes.

Music has been used to help with anxiety, depression, chronic pain, developmental disorders, autism and dementia.
In Article Trend: Neutral
March 4, 2024 (21:15) / "Benzinga" (by Globe Newswire)

Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases ( AD/PD™ ) 2024 Annual Meeting - Biogen ( NASDAQ:BIIB )

New data advances understanding of new approaches to treating Alzheimer's disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc.
In Article Trend: Neutral
March 4, 2024 (21:15) / "GlobeNewswire" (by Biogen Inc.)

Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases ( AD/PD™ ) 2024 Annual Meeting

CAMBRIDGE, Mass., March 04, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced it will present new data from its Alzheimer's disease ( AD ) portfolio at the upcoming International Conference on Alzheimer's and Parkinson's Diseases ( AD/PD™ 2024 ) , taking place March 5-9 in ...
In Article Trend: Neutral
March 4, 2024 (03:37) / "The Financial Express" (by Health Desk)

Biogen needs Leqembi to be successful following discontinuation of Aduhelm, says GlobalData

Biogen's stance at the upcoming AD/PD 2024 International Conference on Alzheimer's disease ( AD ) and Parkinson's disease ( PD ) that will be held on March 5-9 will demonstrate its future plans for AD following the discontinuation of Aduhelm ( aducanumab ) , its anti-amyloid beta ( Aβ ) ...
In Article Trend: Neutral
March 3, 2024 (15:15) / "PR Newswire" (by Pomerantz LLP)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ( "Biogen" or the "Company" ) ( NASDAQ: BIIB ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 2, 2024 (09:53) / "Motley Fool" (by Alex Carchidi)

1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?

Getting its Alzheimer's medicine approved in the European Union could be big.
In Article Trend: Somewhat-Bullish
February 29, 2024 (20:16) / "Benzinga" (by Benzinga Insights)

Biogen Unusual Options Activity - Biogen ( NASDAQ:BIIB )

Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
February 28, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

Here's Why Biogen Inc. ( BIIB ) Fell More Than Broader Market

Biogen Inc. (BIIB) concluded the recent trading session at $221.74, signifying a -0.98% move from its prior day's close.
In Article Trend: Somewhat-Bullish
February 28, 2024 (13:08) / "Zacks Commentary" (by Zacks Equity Research)

Denali's ( DNLI ) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
In Article Trend: Neutral
February 28, 2024 (12:02) / "PR Newswire"

Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers - PR Newswire

Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers PR ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (13:05) / "GlobeNewswire" (by Denali Therapeutics Inc.)

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Denali Therapeutics Inc. ( Nasdaq: DNLI ) , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ( BBB ) for the treatment of neurodegenerative diseases and ...
In Article Trend: Somewhat-Bullish
February 24, 2024 (07:30) / "Benzinga" (by Globe Newswire)

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm - Biogen ( NASDAQ:BIIB )

NEW YORK, Feb. 24, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Biogen Inc. ( "Biogen" or the "Company" ) BIIB on behalf of Biogen stockholders.
In Article Trend: Neutral
February 23, 2024 (12:00) / "Benzinga" (by Globe Newswire)

Biogen's QALSODY® ( tofersen ) , the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP - Biogen ( NASDAQ:BIIB )

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field
In Article Trend: Neutral
February 23, 2024 (12:00) / "GlobeNewswire" (by Biogen Inc.)

Biogen's QALSODY® ( tofersen ) , the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

CAMBRIDGE, Mass., Feb. 23, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for ...
In Article Trend: Neutral
February 22, 2024 (20:04) / "Benzinga" (by Globe Newswire)

Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen's Leqembi, According to Spherix Global Insights Neurologist Survey

EXTON, PA, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- The 2023 announcement of newly approved disease-modifying therapy ( DMT ) Leqembi ( lecanemab ) for Alzheimer's Disease ( AD ) sparked eager anticipation within both the medical community and among families nationwide.
In Article Trend: Neutral
February 22, 2024 (15:29) / "Zacks Commentary" (by Zacks Equity Research)

Ionis ( IONS ) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.
In Article Trend: Neutral
February 21, 2024 (14:13) / "Zacks Commentary" (by Ekta Bagri)

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
In Article Trend: Somewhat-Bullish
February 20, 2024 (19:15) / "CNBC" (by Ashley Capoot)

Healthy Returns: The launch of breakthrough Alzheimer's drug Leqembi is off to a slow start

The Alzheimer's drug Leqembi from Biogen and Eisai is seeing a slow launch, but demand is rising. Meanwhile, headsets are making some users nauseous.
In Article Trend: Neutral
February 20, 2024 (07:36) / "Stocknews.com" (by Defense World Staff)

Biogen ( NASDAQ:BIIB ) Lowered to "Hold" at StockNews.com

Biogen ( NASDAQ:BIIB - Get Free Report ) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday.
In Article Trend: Somewhat-Bullish
February 19, 2024 (20:30) / "Benzinga" (by Benzinga Insights)

Peering Into Biogen's Recent Short Interest - Biogen ( NASDAQ:BIIB )

Biogen's BIIB short percent of float has fallen 18.77% since its last report. The company recently reported that it has 3.06 million shares sold short, which is 2.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.22 days to cover their ...
In Article Trend: Somewhat-Bullish
February 19, 2024 (15:40) / "PR Newswire"

9.18% CAGR growth in Cancer Biologics Market by Product (Monoclonal antibodies, Cell and gene therapy, vaccines ... - PR Newswire

9.18% CAGR growth in Cancer Biologics Market by Product ( Monoclonal antibodies, Cell and gene therapy, vaccines ... PR ...
In Article Trend: Neutral
February 19, 2024 (12:48) / "Stocknews.com" (by StockNews.com Staff)

SIEGY: 3 Industrial Stocks With Future Gains for Investors

The industrial sector, which includes manufacturing, construction, and more, has a solid footing, with several factors such as technological innovation, sustained consumer demand for industrial products and services, growing investments in infrastructure, and favorable government funding and ...
In Article Trend: Somewhat-Bullish
February 17, 2024 (13:49) / "CNBC" (by Kenneth Squire)

Carl Icahn gets two seats on JetBlue's board. Here's how he may help build value

When the legendary investor says he wants board seats, he won't stop until he gets them.
In Article Trend: Somewhat-Bullish
February 16, 2024 (10:48) / "Zacks Commentary" (by Zacks Equity Research)

Ionis' ( IONS ) Olezarsen Gets FDA's Orphan Tag for Rare Disease

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
In Article Trend: Neutral
February 15, 2024 (18:36) / "Zacks Commentary" (by Zacks Equity Research)

Sage Therapeutics ( SAGE ) Q4 Earnings & Revenues Beat Estimates

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
In Article Trend: Neutral
February 15, 2024 (15:19) / "Zacks Commentary" (by Zacks Equity Research)

C4 Therapeutics ( CCCC ) to Report Q4 Earnings: What's in Store?

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
In Article Trend: Neutral
February 15, 2024 (13:28) / "Zacks Commentary" (by Zacks Equity Research)

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
In Article Trend: Neutral
February 15, 2024 (12:00) / "PR Newswire" (by Alkermes plc)

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial ... PR ...
In Article Trend: Somewhat-Bullish
February 14, 2024 (21:47) / "Zacks Commentary" (by Yashwardhan Jain)

Where Are Biotech ETFs Headed After Q4 Earnings?

Look into how Biotech ETFs performed after Q4 earnings.
In Article Trend: Neutral
February 14, 2024 (20:11) / "Benzinga" (by Vandana Singh)

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says - Biogen ( NASDAQ:BIIB )

Tuesday, Biogen Inc BIIB posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency ( CC ) . Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18.
In Article Trend: Somewhat-Bullish
February 14, 2024 (15:12) / "Zacks Commentary" (by Zacks Equity Research)

Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More

Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
In Article Trend: Neutral
February 14, 2024 (12:49) / "Benzinga" (by Avi Kapoor)

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday - Citigroup ( NYSE:C )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. CRWD from $318 to $375.
In Article Trend: Neutral
February 14, 2024 (11:00) / "Zacks Commentary" (by Zacks Investment Research)

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
In Article Trend: Somewhat-Bullish
February 13, 2024 (19:45) / "Motley Fool" (by Motley Fool Transcribing)

Biogen ( BIIB ) Q4 2023 Earnings Call Transcript

BIIB earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
February 13, 2024 (19:13) / "Benzinga" (by Piero Cingari)

Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday? - Airbnb ( NASDAQ:ABNB )

Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. The Consumer Price Index ( CPI ) rose at a 3.1% annual rate in January, down from December's 3.4% ...
In Article Trend: Neutral
February 13, 2024 (17:42) / "Benzinga" (by Vandana Singh)

Why Is Biogen Stock Trading Lower Today? - Biogen ( NASDAQ:BIIB )

On Tuesday, Biogen Inc BIIB posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency ( CC ) . Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18. Multiple sclerosis revenue of $1.17 billion decreased by 8% ...
In Article Trend: Neutral
February 13, 2024 (16:17) / "Zacks Commentary" (by Zacks Equity Research)

Biogen ( BIIB ) Q4 Earnings & Sales Miss Estimates, Stock Falls

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
In Article Trend: Neutral
February 13, 2024 (14:00) / "Zacks Commentary" (by Ekta Bagri)

5 Biotech Stocks to Consider for Your Portfolio in 2024

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
In Article Trend: Somewhat-Bullish
February 13, 2024 (13:46) / "Investors Business Daily" (by ALLISON GATLIN)

Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit

Biogen ( BIIB ) stock slumped early Tuesday after the biotech company reported adjusted earnings of $2.95 per share on $2.39 billion in fourth-quarter sales. On average, analysts polled by FactSet expected Biogen to earn $3.18 per share on $2.47 billion in sales.
In Article Trend: Neutral
February 13, 2024 (13:20) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Lags Q4 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -6.65% and 2.88%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 13, 2024 (12:21) / "MarketWatch" (by Eleanor Laise)

Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment

Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales.
In Article Trend: Neutral
February 13, 2024 (12:03) / "CNBC" (by Annika Kim Constantino)

Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
In Article Trend: Somewhat-Bullish
February 13, 2024 (11:50) / "MarketWatch" (by Barbara Kollmeyer)

Former hedge fund star says this is what will trigger the next bear market.

Former hedge-fund manager Russell Clark says the only thing standing in the way of a bear market for stock is Japan.
In Article Trend: Neutral
February 13, 2024 (11:39) / "Benzinga" (by Shanthi Rexaline)

Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )

Wall Street is poised to open in the red on Tuesday as stock futures declined ahead of the all-important consumer price inflation report for January. Overbought levels could be on traders' minds, especially as the market moves past the crucial phase of the reporting season.
In Article Trend: Neutral
February 13, 2024 (09:26) / "Stocknews.com" (by Defense World Staff)

Biogen ( NASDAQ:BIIB ) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Biogen ( NASDAQ:BIIB - Free Report ) from a hold rating to a buy rating in a research report sent to investors on Monday morning.
In Article Trend: Somewhat-Bullish
February 12, 2024 (21:06) / "Benzinga" (by Globe Newswire)

Biogen Received European Commission Approval for SKYCLARYS® ( omaveloxolone ) , the First Therapy to Treat Friedreich's Ataxia - Biogen ( NASDAQ:BIIB )

Friedreich's ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients
In Article Trend: Neutral
February 12, 2024 (21:06) / "GlobeNewswire" (by Biogen Inc.)

Biogen Received European Commission Approval for SKYCLARYS® ( omaveloxolone ) , the First Therapy to Treat Friedreich's Ataxia

CAMBRIDGE, Mass., Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the European Commission ( EC ) has authorized SKYCLARYS® ( omaveloxolone ) for the treatment of Friedreich's ataxia ( FA ) in adults and adolescents aged 16 years and older.
In Article Trend: Somewhat-Bullish
February 12, 2024 (20:16) / "Benzinga" (by Benzinga Insights)

Looking At Biogen's Recent Unusual Options Activity - Biogen ( NASDAQ:BIIB )

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
In Article Trend: Neutral
February 12, 2024 (17:03) / "Zacks Commentary" (by Zacks Equity Research)

AptarGroup ( ATR ) Inks Deal to Create Digital Health Solutions

AptarGroup (ATR) enters an enterprise agreement with Biogen to create digital health solutions for neurological and rare diseases.
In Article Trend: Somewhat-Bullish
February 12, 2024 (16:48) / "Stocknews.com" (by StockNews.com Staff)

BIIB: Biogen ( BIIB ) : Earnings Alert - Key Insights

Biogen Inc. ( BIIB ) is set to announce its fiscal 2023 fourth-quarter earnings on February 13. Analysts predict a 3.2% year-over-year revenue dip to $2.46 billion, alongside a 21.5% decrease in EPS to $3.18 for the quarter. Nonetheless, the company is undertaking initiatives to expand its growth ...
In Article Trend: Somewhat-Bullish
February 12, 2024 (14:16) / "Zacks Commentary" (by Zacks Equity Research)

Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY

Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.
In Article Trend: Somewhat-Bullish
February 12, 2024 (12:37) / "Business Insider" (by Larry Ramer)

3 Millionaire-Maker Stocks to Buy While the Gettin' Is Good

In order to turn $50,000 into $1 million by investing, you have to find stocks that the Street is underestimating. Of course, to achieve that tremendous feat, investors also have to choose companies that can grow tremendously by exploiting strong trends.
In Article Trend: Somewhat-Bullish
February 9, 2024 (22:30) / "Investors Business Daily" (by Investor's Business Daily)

Cisco Systems, Deere, Occidental And Inflation Data: Investing Action Plan

As the Nasdaq and S&P 500 added yet another week to their phenomenal runs, the Dow flattened out just below 39,000. The coming week sees earnings reports from Dow Jones stocks Coca-Cola ( KO ) and Cisco Systems ( CSCO ) , as well as Deere ( DE ) and Occidental Petroleum ( OXY ) .
In Article Trend: Neutral
February 9, 2024 (19:30) / "Benzinga" (by Benzinga Insights)

Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years - Biogen ( NASDAQ:BIIB )

Biogen BIIB has outperformed the market over the past 20 years by 1.7% on an annualized basis producing an average annual return of 9.28%. Currently, Biogen has a market capitalization of $34.73 billion.
In Article Trend: Somewhat-Bullish
February 9, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)

Ionis' ( IONS ) Eplontersen Gets Fast Track Tag for New Indication

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
In Article Trend: Somewhat-Bullish
February 8, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Stock Sinks As Market Gains: Here's Why

In the most recent trading session, Biogen Inc. (BIIB) closed at $240.30, indicating a -0.1% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
February 8, 2024 (15:32) / "Zacks Commentary" (by Zacks Equity Research)

Can Biogen ( BIIB ) Keep the Beat Streak Alive in Q4 Earnings?

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
In Article Trend: Somewhat-Bullish
February 8, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)

Alkermes ( ALKS ) to Report Q4 Results: Wall Street Expects Earnings Growth

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
February 8, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)

Stay Ahead of the Game With Biogen Inc. ( BIIB ) Q4 Earnings: Wall Street's Insights on Key Metrics

Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
In Article Trend: Neutral
February 8, 2024 (11:00) / "GlobeNewswire" (by Zymeworks Inc.)

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

VANCOUVER, British Columbia, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...
In Article Trend: Somewhat-Bullish
February 8, 2024 (11:00) / "Benzinga" (by Globe Newswire)

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors - Zymeworks ( NASDAQ:ZYME )

VANCOUVER, British Columbia, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ZYME, a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of ...
In Article Trend: Somewhat-Bullish
February 7, 2024 (14:27) / "PR Newswire" (by NeuroSense)

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( "NeuroSense" ) , a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ( "Nasdaq" ) informing the Company ...
In Article Trend: Neutral
February 6, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
February 5, 2024 (12:00) / "GlobeNewswire" (by Lexeo Therapeutics)

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

NEW YORK, Feb. 05, 2024 ( GLOBE NEWSWIRE ) -- Lexeo Therapeutics, Inc. ( Nasdaq: LXEO ) , a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced new executive ...
In Article Trend: Somewhat-Bullish
February 2, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $243.72, denoting a -1.66% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
February 1, 2024 (15:27) / "Zacks Commentary" (by Zacks Equity Research)

Biogen ( BIIB ) to Stop Selling Alzheimer's Disease Drug Aduhelm

Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
In Article Trend: Neutral
February 1, 2024 (15:00) / "Forbes" (by Katie Jennings)

InnovationRx: Show Me The Healthcare Savings

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. here were a whopping two healthtech startups that hit billion-dollar valuations in 2023, compared to 52 unicorns minted during the two years prior, according to a PitchBook analysis.
In Article Trend: Somewhat-Bullish
February 1, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)

Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal

Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.
In Article Trend: Neutral
January 31, 2024 (19:15) / "UPI Business"

Biogen discontinues Alzheimer's drug Aduhelm - .com

Biogen discontinues Alzheimer's drug Aduhelm UPI News ...
In Article Trend: Neutral
January 31, 2024 (17:10) / "Benzinga" (by Vandana Singh)

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines - Biogen ( NASDAQ:BIIB )

Biogen Inc BIIB is pulling the plug on its Aduhelm Alzheimer's disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval.
In Article Trend: Neutral
January 31, 2024 (16:43) / "CNBC" (by Annika Kim Constantino)

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns." ...
In Article Trend: Neutral
January 31, 2024 (15:00) / "Associated Press" (by TOM MURPHY)

Biogen will stop selling its controversial Alzheimer's drug Aduhelm

Biogen will shut down controversial Alzheimer's drug Aduhelm The Associated Press ...
In Article Trend: Neutral
January 31, 2024 (13:59) / "MarketWatch" (by Eleanor Laise)

Biogen drops controversial Alzheimer's drug

Biogen is halting the development and commercialization of the Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to concerns about whether its benefits outweighed its risks.
In Article Trend: Neutral
January 31, 2024 (12:30) / "GlobeNewswire" (by Biogen Inc.)

Biogen to Realign Resources for Alzheimer's Disease Franchise

CAMBRIDGE, Mass., Jan. 31, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced plans to reprioritize its resources in Alzheimer's disease ( AD ) , a strategic therapeutic area expected to drive near and long-term growth.
In Article Trend: Somewhat-Bullish
January 31, 2024 (11:00) / "Forbes" (by Kal Patel M.D.)

Council Post: How Pharma Can Borrow A Page From Digital Health Investors' Playbook

How Pharma Can Borrow A Page From Digital Health Investors' Playbook Forbes ...
In Article Trend: Neutral
January 31, 2024 (06:00) / "GlobeNewswire" (by Sandoz International GmbH)

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® ( natalizumab ) , in Germany

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...
In Article Trend: Somewhat-Bullish
January 31, 2024 (06:00) / "Benzinga" (by Globe Newswire)

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® ( natalizumab ) , in Germany - SANDOZ GROUP AG S/ADR by Sandoz Group AG ( OTC:SDZNY )

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis ( RRMS ) Launch strengthens well-established Sandoz biosimilar ...
In Article Trend: Somewhat-Bullish
January 29, 2024 (22:50) / "Zacks Commentary" (by Zacks Equity Research)

Biogen Inc. ( BIIB ) Laps the Stock Market: Here's Why

Biogen Inc. (BIIB) closed at $247.52 in the latest trading session, marking a +1.1% move from the prior day.
In Article Trend: Somewhat-Bullish
January 29, 2024 (20:59) / "Kiplinger" (by Elaine Silvestrini)

Breakthroughs in Alzheimer's Research Give Cause for Optimism

When Kathleen Mangi asked her husband how he thought her sister was doing, James Mangi grew concerned.
In Article Trend: Neutral
January 29, 2024 (17:10) / "Zacks Commentary" (by Zacks Equity Research)

Will Biogen Inc. ( BIIB ) Beat Estimates Again in Its Next Earnings Report?

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
January 29, 2024 (13:30) / "Benzinga" (by Meg Flippin)

NeuroSense's ( NASDAQ: NRSN ) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 - NeuroSense Therapeutics ( NASDAQ:NRSN ) , Biogen ( NASDAQ:BIIB )

Amyotrophic lateral sclerosis ( ALS ) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis.
In Article Trend: Somewhat-Bullish
January 29, 2024 (10:15) / "PR Newswire"

Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... - PR Newswire

Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... PR ...
In Article Trend: Somewhat-Bullish



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.